Origins, genetic landscape, and emerging therapies of small cell lung cancer
- PMID: 26220992
- PMCID: PMC4526731
- DOI: 10.1101/gad.263145.115
Origins, genetic landscape, and emerging therapies of small cell lung cancer
Abstract
Lung cancer is the leading cause of cancer deaths, with small cell lung cancer (SCLC) representing the most aggressive subtype. Standard treatments have not changed in decades, and the 5-year survival rate has remained <7%. Genomic analyses have identified key driver mutations of SCLC that were subsequently validated in animal models of SCLC. To provide better treatment options, a deeper understanding of the cellular and molecular mechanisms underlying SCLC initiation, progression, metastasis, and acquisition of resistance is required. In this review, we describe the genetic landscape of SCLC, features of the cell of origin, and targeted therapeutic approaches.
Keywords: GEMM; SCLC; cell of origin; driver; neuroendocrine; targeted therapy.
© 2015 Semenova et al.; Published by Cold Spring Harbor Laboratory Press.
Figures
References
-
- Adachi J, Ookawa K, Shiseki M, Okazaki T, Tsuchida S, Morishita K, Yokota J. 1996. Induction of apoptosis but not G1 arrest by expression of the wild-type p53 gene in small cell lung carcinoma. Cell Growth Differ 7: 879–886. - PubMed
-
- Ali FR, Cheng K, Kirwan P, Metcalfe S, Livesey FJ, Barker RA, Philpott A. 2014. The phosphorylation status of Ascl1 is a key determinant of neuronal differentiation and maturation in vivo and in vitro. Development 141: 2216–2224. - PubMed
-
- Azzopardi JG. 1959. Oat-cell carcinoma of the bronchus. J Pathol Bacteriol 78: 513–519. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases